224 related articles for article (PubMed ID: 25868510)
21. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
22. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
23. Strontium ranelate lives to fight another day.
Compston J
Maturitas; 2014 Jun; 78(2):75-6. PubMed ID: 24780410
[No Abstract] [Full Text] [Related]
24. Strontium ranelate--a promising therapeutic principle in osteoporosis.
Boivin G; Doublier A; Farlay D
J Trace Elem Med Biol; 2012 Jun; 26(2-3):153-6. PubMed ID: 22565017
[TBL] [Abstract][Full Text] [Related]
25. Strontium ranelate for the management of osteoporosis.
Lam S; Zouzias K
Consult Pharm; 2008 Jul; 23(7):531-7. PubMed ID: 18764671
[TBL] [Abstract][Full Text] [Related]
26. A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record.
Bolland MJ; Grey A
BMJ Open; 2014 Oct; 4(10):e005787. PubMed ID: 25293384
[TBL] [Abstract][Full Text] [Related]
27. Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture.
Geoffroy V; Chappard D; Marty C; Libouban H; Ostertag A; Lalande A; de Vernejoul MC
Osteoporos Int; 2011 Jan; 22(1):289-97. PubMed ID: 20204596
[TBL] [Abstract][Full Text] [Related]
28. Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.
Atteritano M; Catalano A; Santoro D; Lasco A; Benvenga S
Endocrine; 2016 Jul; 53(1):305-12. PubMed ID: 26304851
[TBL] [Abstract][Full Text] [Related]
29. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
[TBL] [Abstract][Full Text] [Related]
30. [Strontium ranelate in post-menopausal osteoporosis].
Przedlacki J
Endokrynol Pol; 2011; 62 Suppl 2():23-31. PubMed ID: 22125019
[TBL] [Abstract][Full Text] [Related]
31. Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
Collette J; Bruyère O; Kaufman JM; Lorenc R; Felsenberg D; Spector TD; Diaz-Curiel M; Boonen S; Reginster JY
Osteoporos Int; 2010 Feb; 21(2):233-41. PubMed ID: 19436941
[TBL] [Abstract][Full Text] [Related]
32. Strontium still authorised despite an unfavourable opinion of the European Pharmacovigilance committee.
Prescrire Int; 2015 Jan; 24(156):15. PubMed ID: 25729823
[TBL] [Abstract][Full Text] [Related]
33. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis.
Marquis P; Roux C; de la Loge C; Diaz-Curiel M; Cormier C; Isaia G; Badurski J; Wark J; Meunier PJ
Osteoporos Int; 2008 Apr; 19(4):503-10. PubMed ID: 17929073
[TBL] [Abstract][Full Text] [Related]
34. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.
Borgström F; Jönsson B; Ström O; Kanis JA
Osteoporos Int; 2006 Dec; 17(12):1781-93. PubMed ID: 17009083
[TBL] [Abstract][Full Text] [Related]
35. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review.
Boonen S
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842
[TBL] [Abstract][Full Text] [Related]
36. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
Reginster JY; Deroisy R; Jupsin I
Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204
[TBL] [Abstract][Full Text] [Related]
37. Possible benefits of strontium ranelate in complicated long bone fractures.
Alegre DN; Ribeiro C; Sousa C; Correia J; Silva L; de Almeida L
Rheumatol Int; 2012 Feb; 32(2):439-43. PubMed ID: 21120486
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Hiligsmann M; Bruyère O; Reginster JY
Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
[TBL] [Abstract][Full Text] [Related]
39. Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants.
Bain SD; Jerome C; Shen V; Dupin-Roger I; Ammann P
Osteoporos Int; 2009 Aug; 20(8):1417-28. PubMed ID: 19096745
[TBL] [Abstract][Full Text] [Related]
40. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years.
Audran M; Jakob FJ; Palacios S; Brandi ML; Bröll H; Hamdy NA; McCloskey EV
Rheumatol Int; 2013 Sep; 33(9):2231-9. PubMed ID: 23455629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
